AIIMS study proves Covaxin’s effectiveness: Bharat Biotech

HYDERABAD: A day after a study conducted by AIIMS on healthcare professionals, showing Covaxin has a 50% efficacy against symptomatic Covid-19, were published in the Lancet Infectious Diseases journal, Bharat Biotech said the results provide evidence for effectiveness of Covaxin in real life settings.
“An effectiveness result of 50% achieved during the peak Covid-19 delta variant wave in India, in a high risk study population of physicians and health care workers, in a hospital environment, and who are challenged repeatedly with high viral loads, provides insights into the efficacy and effectiveness of Covaxin,” the vaccine developer said in a tweet on Thursday.
The company said these results compare well with the 65.2% efficacy against the Delta variant obtained during the controlled phase III clinical trials of Covaxin that were conducted among the general population. “This study also shows that Covaxin meets the World Health Organisation (WHO) efficacy criteria for Covid-19 vaccines for the dreaded Delta variant,” Bharat Biotech said while commending the AIIMS investigators for the study on Covaxin.
Bharat Biotech’s clinical lead for Covid-19, Raches Ella, too commented on the findings of the study. “Covaxin vaccine effectiveness in health care professionals (HCP’s) is 50%. These findings are encouraging in a community that has a higher force of infection (during the Delta Indian outbreak April-May 2021)…” he tweeted.